Randomized Phase Iii Trial Of Eribulin (E) Versus Standard Weekly Paclitaxel (P) As First- Or Second-Line Therapy For Locally Recurrent Or Metastatic Breast Cancer (Mbc).

Minetta C. Liu,David W. Hillman,Ashley Elizabeth Frith,Alan P. Lyss,Douglas Jay Weckstein,Alvaro Moreno-Aspitia,Nguyet Le-Lindqwister,Claudine Isaacs,Donald B. Wender,DeQuincy Andrew Lewis, John T. Cole,Anthony John Jaslowski,Kendrith M. Rowland,Thomas H. Openshaw,Bret Edward Buckley Friday,Gini F. Fleming,Erik Asmus,Lauren J. Rogak,Ethan M. Basch,Amylou C. Dueck

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览60

暂无评分

摘要

1016Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 tri...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要